^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DK210
i
Other names: DK210, DK2-10
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Deka BioSci
Drug class:
EGFR inhibitor, IL-10 modulator, IL-2 modulator
Related drugs:
11ms
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, DEKA Biosciences
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
EGFR expression • EGFR overexpression • IL10 elevation • IL2 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210
over1year
DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy (ESMO 2023)
Key eligibility criteria include: 1) confirmed progressive disease on at least one line of systemic treatment, 2) EGFR overexpression or amplification documented in histology reports, 3) at least a 4 week or 5 half-lives window since last treatment, and 4) excluding subjects with long QT syndrome, multiple myeloma, multiple sclerosis, myasthenia gravis or uncontrolled infectious, psychiatric, neurologic, or cancer disease. Plasma and tissue samples will be investigated for pharmacodynamic and predictive biomarkers and genetic signatures associated with IFN-gamma secretion, aiming to select subjects for treatment in phase 2.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • IL10 (Interleukin 10)
|
EGFR overexpression
|
DK210
over1year
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, DEKA Biosciences | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
EGFR expression • EGFR overexpression • IL10 elevation • IL2 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210
almost2years
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
P1, N=60, Not yet recruiting, DEKA Biosciences
New P1 trial • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
EGFR overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210
Share via
